Compass Therapeutics Presents Biomarker Data Related To CTX-471 Clinical Activity At SITC Annual Meeting
Compass Therapeutics Presents Biomarker Data Related To CTX-471 Clinical Activity At SITC Annual Meeting
compass therapeutics展示了与CTX-471临床活动相关的生物标志物数据，该数据在海丰国际年会上发布
- New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.
- Predictive biomarkers correlated with response and changes in pharmacodynamic markers were seen in patients treated with CTX-471, a novel anti-CD137 agonist antibody, in an analysis from the Phase 1 monotherapy study.
- 新数据显示，在接受CTX-471单药治疗的患者中，神经细胞粘附分子（NCAm或CD56）的表达水平与治疗反应和疾病控制之间存在相关性。
- 在接受CTX-471治疗的患者中，预测性生物标志物与治疗反应和药效动力学标志物的变化相关，并在1期单药研究的分析中观察到这些现象。CTX-471是一种新型抗CD137激动剂抗体。
资讯热榜
更新时间